| Literature DB >> 28693442 |
Wenting Lao1, Hui Kang2, Guojiang Jin1, Li Chen3, Yang Chu1, Jiao Sun4, Bingqi Sun4.
Abstract
BACKGROUND: Gene polymorphisms impact greatly on a person's susceptibility to pulmonary tuberculosis (PTB). Macrophage receptor with collagenous structure (MARCO) and CD36 are two scavenger receptors (SRs) that can recognize Mycobacterium tuberculosis (Mtb) and play a key role in tuberculosis infection. Gene polymorphisms of MARCO and CD36 may contribute to tuberculosis risk.Entities:
Keywords: CD36; Chinese Han population; MARCO; Pulmonary tuberculosis; Single nucleotide polymorphisms
Mesh:
Substances:
Year: 2017 PMID: 28693442 PMCID: PMC5504633 DOI: 10.1186/s12879-017-2595-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
The demographic characteristics of the study population
| Patients | Controls |
| |
|---|---|---|---|
| Characteristics | |||
| Sex | 0.133 | ||
| Female | 59(29.2%) | 78(36.1) | |
| Male | 143(70.8%) | 138(63.9) | |
| Age yrs | 47.3 ± 19.4 | 48.5 ± 13.4 | 0.44 |
| Smoking | |||
| Smoking | 55(27.2%) | ND | |
| Nonsmoking | 127(62.9%) | ND | |
| Ever Smoking | 20(9.9%) | ND | |
| Laboratory findings | |||
| TP (65-85 g/L) | |||
| < 65 | 49(24.3%) | 21(9.7%) | |
| 65–85 | 148(73.2%) | 195(90.3%) | |
| ND | 5(2.5%) | 0 | |
| Alb (40-55 g/L) | |||
| < 40 | 85(42.1%) | 16(7.4%) | |
| 40–55 | 112(55.4%) | 200(92.6%) | |
| ND | 5(2.5%) | 0 | |
| TG (0.00–1.70 mm/L) | |||
| 0.00–1.70 | 148(73.3%) | 156(72.2%) | |
| > 1.70 | 21(10.4%) | 60(27.8%) | |
| ND | 33(16.3%) | 0 | |
| TC (0.00–5.72 mm/L) | |||
| 0.00–5.72 | 149(73.8%) | 187(86.6%) | |
| > 5.72 | 20(9.9%) | 29(13.4%) | |
| ND | 33(16.3%) | 0 | |
| LDL-C (0.00–3.64 mm/L) | |||
| 0.00–3.64 | 146(72.3%) | 171(79.2%) | |
| > 3.64 | 23(11.4%) | 45(20.8%) | |
| ND | 33(16.3%) | 0 | |
| HDL-C (0.91–1.92 mm/L) | |||
| < 0.91 | 78(38.6%) | 16(7.4%) | |
| 0.91–1.92 | 91(45.1%) | 189(87.5%) | |
| > 1.92 | 0 | 11(5.1%) | |
| ND | 33(16.3%) | 0 | |
| ESR | |||
| Increase | 148(73.3%) | ND | |
| Normal | 40(19.8%) | ND | |
| ND | 14(6.9%) | ND | |
| Clinical phenotype | |||
| Pulmonary tuberculosis | 202 | ||
| Culture positive | 107(53.0%) | ND | |
| Smear positive | 48(23.8%) | ND | |
| Culture/smear positive | 47(23.2%) | ND | |
| Radiographic findings | |||
| Infiltrative PTB | 142(70.3%) | ND | |
| Cavity PTB | 60(29.7%) | ND | |
| System involvment | |||
| TB pleurisy | 22(10.9%) | ND | |
| Disseminated TB | 3(1.5%) | ND | |
| Extra pulmonary involvement | 10(4.9%) | ND | |
| None | 167(82.7%) | ND | |
| Treatment times | |||
| Initial treatment | 98(48.5%) | ND | |
| Retreatment | 104(51.5%) | ND | |
ND, Not determined
Polymerase chain reaction primers and amplicons
| SNP | Direction | Sequence (5′-3′) | Amplicon size (bp) | Annealing temperature (°C) |
|---|---|---|---|---|
| rs12998782 | Forward | AGGAGCTGCAGGTGATAGGAA | 118 | 60.62 |
| Reverse | GGAGCCCAAGGGAATGTGTG | 60.97 | ||
| rs17009726 | Forward | AAACCCACCTGCCCCTATCA | 150 | 60.85 |
| Reverse | CACTAGCCTGCACTGACCAC | 60.67 | ||
| rs1194182 | Forward | CATTTGGCTCAGGTGTCAGG | 134 | 61.65 |
| Reverse | CACAGGCTCTCAACCCTTCAT | 61.59 | ||
| rs3211956 | Forward | CACTTGTGCCAAAGTTGTCC | 126 | 59.19 |
| Reverse | TACATGCAGCAATCCTGGTC | 59.68 | ||
| rs10499859 | Forward | AGTTCTGGGCAAATGTATGTCCT | 185 | 59.99 |
| Reverse | TGCTTGGCTGGTTAGTTTCCA | 60.13 |
Distribution of rs12998782, rs17009726, rs1194182, rs3211956 and rs10499859 alleles, and genotype frequencies in PTB patients and healthy controls
| Patients | Controls | OR | χ2 | 95% CI |
| |
|---|---|---|---|---|---|---|
| ( | ( | |||||
| MARCO | ||||||
| CC | 117 (57.9%) | 131(60.6%) | Reference | Reference | ||
| CT | 66 (32.7%) | 77 (35.7%) | 0.974 | 0.038 | 0.750–1.266 | 0.845 |
| TT | 19 (9.4%) | 8 (3.7%) | 2.427 | 5.24 | 1.100–5.357 | 0.022 |
| CC + CT | 183 (90.6%) | 208(96.3%) | Reference | Reference | ||
| TT | 19 (9.4%) | 8 (3.7%) | 2.54 | 5.617 | 1.137–5.672 | 0.018 |
| Allele | ||||||
| C | 300 (74.3%) | 339(78.5%) | Reference | Reference | ||
| T | 104 (25.7%) | 93 (21.5%) | 1.196 | 2.059 | 0.936–1.527 | 0.151 |
| rs17009726 | ||||||
| AA | 156 (77.2%) | 163(75.5%) | Reference | Reference | ||
| AG | 46 (22.8%) | 53 (24.5%) | 0.928 | 0.18 | 0.657–1.311 | 0.671 |
| Allele | ||||||
| A | 358 (88.6%) | 379(87.7%) | Reference | Reference | ||
| G | 46 (11.4%) | 53 (12.3%) | 0.928 | 0.156 | 0.640–1.345 | 0.693 |
| CD36 | ||||||
| CC | 45 (22.3%) | 51 (23.6%) | Reference | Reference | ||
| CG | 126 (62.4%) | 99 (45.8%) | 1.116 | 2.251 | 0.965–1.291 | 0.134 |
| GG | 31 (15.3%) | 66 (30.6%) | 0.723 | 4.497 | 0.528–0.990 | 0.034* |
| CC + CG | 171 (84.7%) | 150(69.4%) | Reference | Reference | ||
| GG | 31 (15.3%) | 66 (30.6%) | 0.502 | 13.549 | 0.343–0.735 | <0.01* |
| Allele | ||||||
| C | 216 (53.5%) | 201(46.5%) | Reference | Reference | ||
| G | 188 (46.5%) | 231(54.5%) | 0.87 | 4.019 | 0.759–0.998 | 0.045* |
| rs3211956 | ||||||
| GG | 8 (4.0%) | 9(4.1%) | Reference | Reference | ||
| GT | 58 (28.7%) | 56 (25.9%) | 1.02 | 0.086 | 0.894–1.164 | 0.769 |
| TT | 136(67.3%) | 151(70.0%) | 1.001 | 0.001 | 0.947–1.057 | 0.979 |
| Allele | ||||||
| G | 74 (18.3%) | 74 (17.1%) | Reference | Reference | ||
| T | 330 (81.7%) | 358(82.9%) | 0.986 | 0.202 | 0.925–1.050 | 0.653 |
| rs10499859 | ||||||
| AA | 79 (39.1%) | 57 (26.4%) | Reference | Reference | ||
| AG | 109 (54.0%) | 102(47.2%) | 0.904 | 1.377 | 0.764–1.069 | 0.241 |
| GG | 14 (6.9%) | 57 (26.4%) | 0.301 | 27.756 | 0.180–0.505 | <0.001 |
| AA + AG | 188 (93.1%) | 159(73.6%) | Reference | Reference | ||
| GG | 14 (6.9%) | 57 (26.4%) | 0.263 | 28.028 | 0.151–0.456 | <0.001 |
| Allele | ||||||
| A | 267 (66.1%) | 216(50.0%) | Reference | Reference | ||
| G | 137 (33.9%) | 216(50.0%) | 0.678 | 22.152 | 0.575–0.800 | <0.001 |
OR odds ratio, 95% CI 95% confidence interval
*P< 0.05 indicates statistical significance
Distribution of combinations of rs12998782 and rs1194182, or rs12998782 and rs10499859 genotype frequencies in PTB patients and healthy controls
| Patients | Controls | ||||||
|---|---|---|---|---|---|---|---|
| ( | ( | OR | χ2 | 95% CI |
| ||
| rs12998782 | rs1194182 | ||||||
| CC | CC | 29 (14.3%) | 31 (14.4%) | Reference | Reference | ||
| CT | CC | 14 (6.9%) | 16 (7.4%) | 0.956 | 0.022 | 0.532–1.718 | 0.881 |
| TT | CC | 2 (1.0%) | 4 (1.9%) | 0.565 | 0.075 | 0.111–2.873 | 0.785 |
| CC | CG | 70(34.7%) | 60(27.8%) | 1.072 | 0.5 | 0.883–1.303 | 0.48 |
| CT | CG | 43(21.3%) | 37(17.1%) | 1.098 | 0.403 | 0.882–1.456 | 0.526 |
| TT | CG | 13 (6.4%) | 2 (0.9%) | 5.107 | 7.156 | 1.238–21.069 | 0.007* |
| CC | GG | 18 (8.9%) | 40(18.5%) | 0.68 | 3.682 | 0.448–1.031 | 0.055 |
| CT | GG | 9 (4.5%) | 24(11.1%) | 0.543 | 3.908 | 0.285–1.034 | 0.048 |
| TT | GG | 4 (2.0%) | 2 (0.9%) | 2 | 0.183 | 0.393–10.181 | 0.669 |
| rs12998782 | rs10499859 | ||||||
| CC | AA | 43(21.3%) | 39(18.1%) | Reference | Reference | ||
| CT | AA | 31(15.3%) | 17 (7.9%) | 1.38 | 1.821 | 0.855–2.228 | 0.177 |
| TT | AA | 5 (2.5%) | 1 (0.5%) | 4.167 | 1.087 | 0.507–34.218 | 0.297 |
| CC | AG | 66(32.7%) | 57(26.4%) | 1.02 | 0.029 | 0.815–1.276 | 0.864 |
| CT | AG | 32(15.8%) | 40(18.5%) | 0.843 | 0.981 | 0.599–1.185 | 0.322 |
| TT | AG | 11 (5.4%) | 5 (2.3%) | 1.793 | 1.44 | 0.673–4.773 | 0.23 |
| CC | GG | 8 (4.0%) | 35(16.2%) | 0.332 | 13.369 | 0.168–0.655 | <0.001* |
| CT | GG | 3 (1.5%) | 20 (9.2%) | 0.192 | 11.324 | 0.061–0.608 | 0.001* |
| TT | GG | 3 (1.5%) | 2 (0.9%) | 1.337 | 0.108 | 0.235–7.609 | 0.742 |
OR odds ratio, 95% CI 95% confidence interval
*P< 0.05 indicates statistical significance
Fig. 1Pairwise linkage disequilibrium (LD) pattern of CD36 region
Fig. 2Pairwise linkage disequilibrium (LD) pattern of MARCO region
Haplotype frequencies constructed with SNPs in the PTB group and the control group (rs1194182, rs10499859)
| Haplotype | Frequency | Case ( | Controls ( | χ2 |
|
|---|---|---|---|---|---|
| CA | 0.424 | 0.504(203.6) | 0.35(151.2) | 20.261 | <0.001* |
| GG | 0.347 | 0.308(124.6) | 0.382(165.2) | 5.044 | 0.0247* |
| GA | 0.155 | 0.157(63.4) | 0.152(65.8) | 0.034 | 0.8541 |
| CG | 0.074 | 0.031(12.4) | 0.115(49.8) | 21.699 | <0.001* |
*P< 0.05 indicates statistical significance
Stratified analysis of distribution of rs12998782, rs1194182 and rs10499859 alleles, and genotype frequencies in PTB patients and healthy controls according to the levels of albumin
| ALB < 40(g/L) | ALB > 40(g/L) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients | Controls | OR | χ2 | 95% CI |
| Patients | Controls | OR | χ2 | 95% CI |
| |
| ( | ( | ( | ( | |||||||||
| MARCO | ||||||||||||
| CC | 50 | 11 | 64 | 120 | ||||||||
| CT | 28 | 5 | 1.232 | 0.126 | 0.389–3.906 | 0.723 | 36 | 72 | 0.952 | 0.036 | 0.576–1.575 | 0.849 |
| TT | 7 | 0 | − | − | − | − | 12 | 8 | 2.813 | 4.907 | 1.094–7.233 | 0.027* |
| CC + CT | 78 | 16 | 100 | 192 | ||||||||
| TT | 7 | 0 | − | − | − | − | 12 | 8 | 2.88 | 5.395 | 1.140–7.275 | 0.02* |
| Allele | ||||||||||||
| C | 78 | 16 | 100 | 192 | ||||||||
| T | 92 | 16 | 1.179 | 0.194 | 0.554–2.511 | 0.688 | 124 | 208 | 1.145 | 0.65 | 0.824–1.59 | 0.42 |
| CD36 | ||||||||||||
| CC | 18 | 3 | 26 | 49 | ||||||||
| CG | 53 | 8 | 1.104 | <0.0001 | 0.246–4.617 | 1 | 70 | 92 | 1.434 | 1.553 | 0.812–2.531 | 0.213 |
| GG | 15 | 5 | 0.5 | 0.222 | 0.102–2.444 | 0.638 | 16 | 61 | 0.494 | 3.664 | 0.239–1.023 | 0.056 |
| CC + CG | 71 | 11 | 96 | 141 | ||||||||
| GG | 15 | 5 | 0.465 | 0.873 | 0.141–1.535 | 0.35 | 16 | 61 | 0.385 | 9.857 | 0.21–0.708 | 0.002* |
| Allele | ||||||||||||
| C | 89 | 14 | 122 | 190 | ||||||||
| G | 83 | 18 | 0.725 | 0.69 | 0.339–1.551 | 0.406 | 102 | 214 | 0.742 | 3.186 | 0.535–1.03 | 0.074 |
| rs10499859 | ||||||||||||
| AA | 35 | 5 | 42 | 52 | ||||||||
| AG | 42 | 7 | 0.857 | 0.06 | 0.25–2.939 | 0.806 | 64 | 95 | 0.834 | 0.476 | 0.498–1.397 | 0.49 |
| GG | 8 | 4 | 0.286 | 2.799 | 0.062–1.31 | 0.094 | 6 | 53 | 0.14 | 20.052 | 0.055–0.385 | <0.001* |
| AA + AG | 77 | 12 | 106 | 147 | ||||||||
| GG | 8 | 4 | 0.312 | 3.125 | 0.081–1.197 | 0.077 | 6 | 53 | 0.157 | 20.929 | 0.065–0.379 | <0.001* |
| Allele | ||||||||||||
| A | 112 | 17 | 148 | 199 | ||||||||
| G | 58 | 15 | 0.587 | 1.899 | 0.274–1.259 | 0.168 | 76 | 201 | 0.508 | 15.495 | 0.362–0.714 | <0.001* |
OR odds ratio, 95% CI 95% confidence interval
*P< 0.05 indicates statistical significance